James Martin departed as Co-Chief Executive Officer at Cocrystal Pharma, Inc..
“Mr. Sapirstein replaces Sam Lee and James Martin, who served as the Company’s Co-Chief Executive Officers.”
Cocrystal Pharma, Inc. — fact timeline
Source-grounded facts extracted from Cocrystal Pharma, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Sam Lee departed as Co-Chief Executive Officer at Cocrystal Pharma, Inc..
“Mr. Sapirstein replaces Sam Lee and James Martin, who served as the Company’s Co-Chief Executive Officers.”
James Sapirstein was appointed as Chief Executive Officer at Cocrystal Pharma, Inc..
“the Board of Directors (the “Board”) of Cocrystal Pharma, Inc. (the “Company”) appointed James Sapirstein as the Chief Executive Officer of the Company, effective immediately”
Cocrystal Pharma, Inc. reported financial results for the year ended December 31, 2025.
“Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the year ended December 31, 2025”
Cocrystal Pharma, Inc. issued 739,426 units of unit to four accredited investors (the “Purchasers”) for $1.39 per unit; gross proceeds were $1.03 million.
“On October 28, 2025, Cocrystal Pharma, Inc., a Delaware corporation (the “Company” or “Cocrystal”) entered into a Securities Purchase Agreement (“SPA”) with four accredited investors (the “Purchasers”) under which the Purchasers purchased a total of 739,426 units of the Company’s securities. The units were priced at-the-market under the rules of the Nasdaq Stock Market at a purchase price of $1.39 per unit. Each unit consisted of one share of common stock and one warrant to purchase two shares of common stock at an exercise price of $1.24 per share over a 27-month period.”
Cocrystal Pharma, Inc. issued warrants to acquire up to an aggregate of 207,353 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC for cash fee equal to 7.0% of the aggregate gross proceeds, a management fee equal to 1.0% of the aggregate gross proceeds, reimbursement of certain expenses.
“medicines for use in the treatment of human viral diseases. 2 Under the SPA, no later than October 10, 2025, the Company is required to file a registration statement on Form S-1 registering the resale of the shares of Common Stock issued or issuable upon exercise of the Investor Warrants (the “Resale Registration Statement”). The Company is required to”
Cocrystal Pharma, Inc. issued warrants to purchase up to an aggregate of 5,529,420 shares of warrant to accredited investors for initial exercise price of $1.50 per share.
“and (ii) in a concurrent private placement, warrants to purchase up to an aggregate of 5,529,420 shares of Comon Stock (“the Investor Warrants”), at an initial exercise price of $1.50 per share (the “Private Placement” and together with the Registered Direct Offering, the “Offering”). The Shares were offered at-the-market under rules of The Nasdaq Stock Market,”
Cocrystal Pharma, Inc. issued 2,764,710 shares of common stock to accredited investors for at a price of $1.70 per share.
“in a registered direct offering, an aggregate of 2,764,710 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price of $1.70 per share (the “Registered Direct Offering”) and (ii) in a concurrent private placement, warrants to purchase up to an aggregate of 5,529,420 shares of Comon Stock (“the Investor”
Cocrystal Pharma, Inc.: Amended the quorum requirement to one third of the voting power of outstanding shares of all classes or series of voting stock (effective 2025-06-17).
“On June 17, 2025, the Board of Directors of Cocrystal Pharma, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated Bylaws to the quorum requirement to provide that one third of the aggregate voting power of the outstanding shares of all classes or series of voting stock then entitled to vote, represented in person or by proxy, shall constitute a quorum at a meeting of stockholders (the “Amendment”).”
Cocrystal Pharma, Inc. reported financial results for Q1 2024.
“Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three months ended March 31, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.”
Cocrystal Pharma, Inc. reported financial results for the 12 months ended December 31, 2023.
“Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the 12 months ended December 31, 2023, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.”
Cocrystal Pharma, Inc. terminated License Agreements with Kansas State University Research Foundation valued at Early termination of License Agreements dated February 12, 2020 and April 19, 2020 (effective 2024-03-29).
“provided notice to Kansas State University Research Foundation of the Company’s election to terminate the License Agreements (the “Agreements”) dated February 12, 2020 and April 19, 2020. The terminations, which were made due to the Company’s determination that further development efforts under the Agreements would be futile, are effective on March 29, 2024.”
Cocrystal Pharma, Inc. terminated Exclusive License and Research Collaboration Agreement with Merck Sharp & Dohme LLC (effective 2023-12-15).
“On December 15, 2023, Cocrystal Pharma, Inc. (the “Company”) received written notice from Merck Sharp & Dohme LLC (“Merck”) of Merck’s election to terminate the Exclusive License and Research Collaboration Agreement (the “Agreement”), dated January 2, 2019, by and between the Company and Merck, with respect to the collaboration with Merck on the development of influenza A/B antiviral compounds.”
Cocrystal Pharma, Inc. reported financial results for three and nine months ended September 30, 2023.
“On November 13, 2023, Cocrystal Pharma, Inc. (the "Company") issued a press release announcing its results of operations for the fiscal quarter ended September 30, 2023.”
Cocrystal Pharma, Inc. reported financial results for the three and six months ended June 30, 2023.
“Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the three and six months ended June 30, 2023”
Cocrystal Pharma, Inc. shareholders approved Non-binding advisory approval of compensation of the Company's named executive officers at the 2023-06-08 meeting.
“Proposal 3 . The Company’s stockholders voted to approve a non-binding advisory basis for compensation of the Company’s named executive officers. Votes For Votes Against Abstentions 3,668,840 976,339 58,387”
Cocrystal Pharma, Inc. shareholders approved Ratification of the appointment of Weinberg & Company as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-08 meeting.
“Proposal 2 . The Company’s stockholders voted to ratify the appointment of Weinberg & Company as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. Votes For Votes Against Abstentions 6,594,971 186,279 32,863”
Cocrystal Pharma, Inc. shareholders approved Election of six members of the Board of Directors for a one-year term expiring at the next annual meeting of stockholders at the 2023-06-08 meeting.
“On June 8, 2023, the 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”) of Cocrystal Pharma, Inc. (the “Company”) was held. At the 2023 Annual Meeting, the Company’s stockholders voted on (i) the election of six members of the Company’s Board of Directors for a one-year term expiring at the next annual meeting of stockholders (Proposal 1); (ii) ratification of the appointment of Weinberg & Company as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 (Proposal 2); (iii) approval of a non-binding advisory basis for compensation of the Company’s named executive officers (Proposal 3); and (iv) approval of an adjournment of the 2023 Annual Meeting to a later date or time, if necessary, to permit further solicitation and vote of proxies if there are not sufficient votes at the time of the Annual Meeting to approve any of the proposals presented for a vote at the 2023 Annual Meeting, all as described in more detail in the Com”
Cocrystal Pharma, Inc. reported financial results for three months ended March 31, 2023.
“On May 15, 2023, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal quarter ended March 31, 2023.”
Fred Hassan was appointed as director at Cocrystal Pharma, Inc..
“On April 20, 2023, the Board of Directors of Cocrystal Pharma, Inc. (the “Company”) appointed Fred Hassan as a director, thereby increasing the number of directors to six.”
Cocrystal Pharma, Inc. entered into Securities Purchase Agreement with Fred Hassan and Frost Gamma Investments Trust valued at $4,000,000 (effective 2023-04-04).
“On April 4, 2023, Cocrystal Pharma, Inc. (the “Company”) entered into a Securities Purchase Agreement (“SPA”) with two accredited investors (the “Purchasers”) whereby the Purchasers agreed to purchase a total of 2,030,458 shares of common stock at a price of $1.97 per share for a total purchase price of $4,000,000 in two equal $2,000,000 investments.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.